Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27451617 | 0.98 | AR (0.50) | ARP4HBCYP19A1ALDH1A1AOX1 | |
| Propanol SCHEMBL28210032 | 0.90 | CYP19A1 (0.46) | ARP4HBCYP19A1ALDH1A1AOX1 | |
| SCHEMBL459931 | 0.84 | MAOB (0.55) | ARP4HBCYP19A1ALDH1A1TSHR | |
| SCHEMBL29804271 | 0.84 | MAOB (0.55) | ARP4HBCYP19A1ALDH1A1TSHR | |
| SCHEMBL29490258 | 0.81 | AR (0.66) | ARALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL509522 | 0.81 | AR (0.66) | ARALDH1A1PDE4APDE4BPDE4C | |
| SCHEMBL4669307 | 0.80 | ALDH1A1 (0.53) | ARP4HBALDH1A1 | |
| SCHEMBL7516469 | 0.80 | ALDH1A1 (0.47) | ALDH1A1AOX1CYP1A2MAPTTSHR | |
| SCHEMBL3578998 | 0.80 | ALDH1A1 (0.47) | ALDH1A1AOX1CYP1A2MAPTTSHR | |
| SCHEMBL910063 | 0.80 | ALDH1A1 (0.52) | ALDH1A1AOX1CYP1A2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-113527130-B | Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound | 兰州大学 | 2023-07-18 | — | — | CN | claimed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | claimed |
| CN-113527130-A | Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound | 兰州大学 | 2021-10-22 | — | — | CN | claimed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | claimed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | claimed |
| CN-110903253-B | Quinazolinone compound and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2020-12-25 | — | — | CN | claimed |
| CN-110903253-A | Quinazolinone compound and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2020-03-24 | — | — | CN | claimed |
| CN-105503749-A | Synthetic method of 4-(3-chlorine-4-fluorophenyl)-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline | NANJING EAST SUNSCREEN PHARMACEUTICAL CO LTD | 2016-04-20 | — | — | CN | claimed |
| CN-105461602-A | Preparation method of chiral S/R-3-ethoxy-4-methoxy-alpha[(methylsulfonyl)methyl] benzyl alcohol | NAT UNIV DONG HWA | 2016-04-06 | — | — | CN | claimed |
| CN-105330586-A | Preparation method of Apremilast | NAT UNIV DONG HWA | 2016-02-17 | — | — | CN | claimed |
| CN-105218463-A | The synthetic method of Gefitinib | UNIV SHENYANG PHARMACEUTICAL | 2016-01-06 | — | — | CN | claimed |
| US-20100217027-A1 | PROCESS FOR PRODUCTION PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT ORTHO POSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-08-26 | — | — | US | claimed |
| EP-2199271-A1 | PROCESS FOR PRODUCTION OF PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT ORTHO POSITION | Mitsubishi Gas Chemical Company, Inc. (JP) | 2010-06-23 | — | — | EP | claimed |
| WO-2010026375-A1 | PHARMACEUTICAL PREPARATION COMPRISING A CATECHIN | LARKINS NICHOLAS JOHN (GB) | 2010-03-11 | — | — | WO | claimed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | claimed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | claimed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | claimed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | claimed |
| CN-119912397-A | Gefitinib intermediate impurity YKYZ-C-GF-3, and preparation method and control method thereof | 江苏天士力帝益药业有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250049808-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | 2025-02-13 | — | — | US | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117700376-A | N-benzyl benzamide compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2024-03-15 | — | — | CN | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-116723845-A | Crystalline forms of deoxycytidine kinase inhibitors and uses thereof | 特雷西拉公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4237421-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-113527130-B | Synthesis method of alpha-amide, alpha-aryl quaternary carboketone compound | 兰州大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-116410144-A | Gefitinib new impurity compound and synthesis method thereof | 北京新领先医药科技发展有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-111620764-B | Selective ether bond cleavage method of aryl alkyl ether | 荆楚理工学院 | 2023-05-05 | — | — | CN | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-218189639-U | Reation kettle for bio-pharmaceuticals | 福建智罗科技有限公司 | 2023-01-03 | — | — | CN | disclosed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | disclosed |
| US-11446307-B2 | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof | Trethera Corporation (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446307-B2 | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof | Trethera Corporation (US) | 2022-09-20 | — | — | US | disclosed |
| CN-114920704-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114736171-A | Preparation method of gefitinib intermediate | 北京济美堂医药研究有限公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-111825829-B | Triazine ring structure-containing bio-based epoxy resin and preparation method thereof | 大连理工大学 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022094409-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20220135555-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | 2022-05-05 | — | — | US | disclosed |
| US-20220135555-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | 2022-05-05 | — | — | US | disclosed |
| US-20220133735-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | 2022-05-05 | — | — | US | disclosed |
| US-20220133735-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation | 2022-05-05 | — | — | US | disclosed |
| WO-2022094409-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | Trethera Corporation (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | disclosed |
| CN-108779111-B | Deoxycytidine kinase binding compounds | 加利福尼亚大学董事会 | 2021-11-12 | — | — | CN | disclosed |
| CN-108821930-B | Ether bond cracking method of phenyl alkyl ether | 荆楚理工学院 | 2021-11-05 | — | — | CN | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113527130-A | Synthetic method of alpha-amide and alpha-aryl quaternary carbon ketone compound | 兰州大学 | 2021-10-22 | — | — | CN | disclosed |
| EP-3861001-A1 | BORON CONTAINING PDE4 INHIBITORS | Pfizer Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-113166177-A | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110747489-B | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2021-05-07 | — | — | CN | disclosed |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PFIZER INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | disclosed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | disclosed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | disclosed |
| CN-110903253-B | Quinazolinone compound and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2020-12-25 | — | — | CN | disclosed |
| CN-111825829-A | Triazine ring structure-containing bio-based epoxy resin and preparation method thereof | 大连理工大学 | 2020-10-27 | — | — | CN | disclosed |
| CN-107473916-B | Ether bond breaking method of phenyl alkyl ether | 荆楚理工学院 | 2020-09-22 | — | — | CN | disclosed |
| CN-111620764-A | Selective ether bond breaking method of aryl alkyl ether | 荆楚理工学院 | 2020-09-04 | — | — | CN | disclosed |
| CN-106866377-B | Ether bond breaking method of phenyl alkyl ether | 荆楚理工学院 | 2020-06-09 | — | — | CN | disclosed |
| WO-2020070651-A1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-110903253-A | Quinazolinone compound and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2020-03-24 | — | — | CN | disclosed |
| CN-105658648-B | Deoxycytidine kinase inhibitors | 加利福尼亚大学董事会 | 2020-03-17 | — | — | CN | disclosed |
| US-10570124-B2 | Deoxycytidine kinase binding compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570124-B2 | Deoxycytidine kinase binding compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110776471-A | Synthesis method of medicine for inhibiting tumor cells | 王爱平 | 2020-02-11 | — | — | CN | disclosed |
| CN-110747489-A | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2020-02-04 | — | — | CN | disclosed |
| CN-109627222-A | A kind of Gefitinib intermediate preparation method | 南京天越星生物技术有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-10251886-B1 | 4-anilinoquinazoline derivative and albumin conjugates thereof | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2019-04-09 | — | — | US | disclosed |
| US-10251886-B1 | 4-anilinoquinazoline derivative and albumin conjugates thereof | NATIONAL CHIAO TUNG UNIVERSITY (TW) | 2019-04-09 | — | — | US | disclosed |
| US-20190016714-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-17 | — | — | US | disclosed |
| US-20190016714-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-17 | — | — | US | disclosed |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3400224-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | The Regents of The University of California (US) | 2018-11-14 | — | — | EP | disclosed |
| CN-108779111-A | In conjunction with the compound of deoxycytidine kinase | 加利福尼亚大学董事会 | 2018-11-09 | — | — | CN | disclosed |
| US-9981961-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981961-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981961-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-3307715-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| CN-107586279-A | A kind of new synthetic method of Gefitinib | 江苏正大清江制药有限公司 | 2018-01-16 | — | — | CN | disclosed |
| US-20170204090-A1 | DEOXYCYTIDINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-20 | — | — | US | disclosed |
| US-20170204090-A1 | DEOXYCYTIDINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-20 | — | — | US | disclosed |
| US-20170204090-A1 | DEOXYCYTIDINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-20 | — | — | US | disclosed |
| WO-2017120585-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017120585-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-13 | — | — | WO | disclosed |
| US-9688673-B2 | Deoxycytidine kinase binding compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688673-B2 | Deoxycytidine kinase binding compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688673-B2 | Deoxycytidine kinase binding compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-27 | — | — | US | disclosed |
| US-9642836-B2 | Isotopologues of isoindole derivatives | CELGENE CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9617227-B2 | Process of preparing a quinazoline derivative | SCINOPHARM (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2017-04-11 | — | — | US | disclosed |
| US-9598404-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598404-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598404-B2 | Deoxycytidine kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016198374-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| US-20160237076-A1 | DEOXYCYTIDINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-18 | — | — | US | disclosed |
| US-20160237076-A1 | DEOXYCYTIDINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-18 | — | — | US | disclosed |
| US-20160237076-A1 | DEOXYCYTIDINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-18 | — | — | US | disclosed |
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | SCIANDA (CHANGSHU) PHARMACEUTICALS, LTD. (CN) | 2016-07-14 | — | — | US | disclosed |
| EP-3033340-A2 | DEOXYCYTIDINE KINASE INHIBITORS | The Regents of The University of California (US) | 2016-06-22 | — | — | EP | disclosed |
| CN-105658648-A | Deoxycytidine kinase inhibitors | 加利福尼亚大学董事会 | 2016-06-08 | — | — | CN | disclosed |
| CN-105503749-A | Synthetic method of 4-(3-chlorine-4-fluorophenyl)-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline | NANJING EAST SUNSCREEN PHARMACEUTICAL CO LTD | 2016-04-20 | — | — | CN | disclosed |
| CN-105503749-A | Synthetic method of 4-(3-chlorine-4-fluorophenyl)-7-methoxyl-6-[3-(4-morpholinyl) propoxy] quinazoline | NANJING EAST SUNSCREEN PHARMACEUTICAL CO LTD | 2016-04-20 | — | — | CN | disclosed |
| CN-105461602-A | Preparation method of chiral S/R-3-ethoxy-4-methoxy-alpha[(methylsulfonyl)methyl] benzyl alcohol | NAT UNIV DONG HWA | 2016-04-06 | — | — | CN | disclosed |
| CN-105461602-A | Preparation method of chiral S/R-3-ethoxy-4-methoxy-alpha[(methylsulfonyl)methyl] benzyl alcohol | NAT UNIV DONG HWA | 2016-04-06 | — | — | CN | disclosed |
| CN-105330586-A | Preparation method of Apremilast | NAT UNIV DONG HWA | 2016-02-17 | — | — | CN | disclosed |
| CN-105330586-A | Preparation method of Apremilast | NAT UNIV DONG HWA | 2016-02-17 | — | — | CN | disclosed |
| CN-105218463-A | The synthetic method of Gefitinib | UNIV SHENYANG PHARMACEUTICAL | 2016-01-06 | — | — | CN | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-20150258063-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | AMGEN INC. | 2015-09-17 | — | — | US | disclosed |
| US-9045417-B2 | Isotopologues of isoindole derivatives | CELGENE CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| WO-2015023776-A2 | DEOXYCYTIDINE KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | WO | disclosed |
| US-20140194485-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | CELGENE CORPORATION (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130336883-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013180403-A1 | PROCESS FOR PREPARING GEFITINIB AND AN INTERMEDIATE USED FOR PREPARING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-05 | — | — | WO | disclosed |
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| CN-102088979-B | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy}quinazoline | ASTRAZENECA AB | 2013-10-16 | — | — | CN | disclosed |
| CN-103304491-A | Preparation method of gefitinib | LIANYUNGANG SHENGHE BIOTECHNOLOGY CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8350029-B2 | Process for the preparation of gefitinib | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012122368-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012122368-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012083153-A1 | OLIGOMER-CONTAINING APREMILAST MOIETY COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083153-A1 | OLIGOMER-CONTAINING APREMILAST MOIETY COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| EP-2421827-A2 | PROCESS FOR THE PREPARATION OF 4-(3-CHLORO-2-FLUORO- ANILINO)-7-METHOXY-6- { [1-(N-METHYLCARBAMOYLMETHYL)- PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8101619-B2 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-01-24 | — | — | US | disclosed |
| US-8101619-B2 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-01-24 | — | — | US | disclosed |
| US-8088782-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-8088782-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-8062429-B2 | Methods of cleaning semiconductor devices at the back end of line using amidoxime compositions | EKC TECHNOLOGY, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-7964531-B2 | 3-phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same | MITSUI CHEMICALS AGRO, INC. (JP) | 2011-06-21 | — | — | US | disclosed |
| CN-102088979-A | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy}quinazoline | ASTRAZENECA AB | 2011-06-08 | — | — | CN | disclosed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010119877-A1 | PROCESS FOR PRODUCTION OF AMIDINE DERIVATIVE | 味の素株式会社 (JP) | 2010-10-21 | — | — | WO | disclosed |
| US-20100217027-A1 | PROCESS FOR PRODUCTION PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT ORTHO POSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2199271-A1 | PROCESS FOR PRODUCTION OF PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT ORTHO POSITION | Mitsubishi Gas Chemical Company, Inc. (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | CIPLA LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100105595-A1 | COMPOSITION COMPRISING CHELATING AGENTS CONTAINING AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | disclosed |
| US-7705145-B2 | Process for the preparation of 4-(3′-chloro-4′-fluoroanilino) -7-methoxy-6-(3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2010-04-27 | — | — | US | disclosed |
| WO-2010026375-A1 | PHARMACEUTICAL PREPARATION COMPRISING A CATECHIN | LARKINS NICHOLAS JOHN (GB) | 2010-03-11 | — | — | WO | disclosed |
| US-20100043823-A1 | METHODS OF CLEANING SEMICONDUCTOR DEVICES AT THE BACK END OF LINE USING AMIDOXIME COMOSITIONS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2010-02-25 | — | — | US | disclosed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | disclosed |
| US-20100041555-A1 | 3-Phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same | MITSUI CHEMICALS AGRO, INC. (JP) | 2010-02-18 | — | — | US | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-7608563-B2 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | MITSUI AGRO CHEMICALS, INC. (JP) | 2009-10-27 | — | — | US | disclosed |
| EP-1426365-B9 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | MITSUI CHEMICALS AGRO INC (JP) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| EP-1426365-B1 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | SANKYO AGRO CO LTD (JP) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009085072-A1 | COMPOSITION COMPRISING CHELATING AGENTS CONTAINING AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC (US) | 2009-07-09 | — | — | WO | disclosed |
| JP-2009126784-A | METHOD FOR PRODUCING 2-IODO-3,4-DIMETHOXYBENZONITRILE | MITSUBISHI GAS CHEM CO INC | 2009-06-11 | — | — | JP | disclosed |
| US-20090137191-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090133716-A1 | METHODS OF POST CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING USING AMIDOXIME COMPOSITIONS | EKC TECHNOLOGY, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090130849-A1 | CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING COMPOSITION COMPRISING AMIDOXIME COMPOUNDS AND ASSOCIATED METHOD FOR USE | EKC TECHNOLOGY, INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2009058274-A1 | CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING COMPOSITION COMPRISING AMIDOXIME COMPOUNDS AND ASSOCIATED METHOD FOR USE | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058272-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058288-A1 | AMIDOXIME COMPOUNDS AS CHELATING AGENTS IN SEMICONDUCTOR PROCESSES | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058278-A1 | METHODS OF CLEANING SEMICONDUCTOR DEVICES AT THE BACK END OF LINE USING AMIDOXIME COMPOSITIONS | EKC TECHNOLOGY, INC (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058275-A1 | METHODS OF POST CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING USING AMIDOXIME COMPOSITIONS | EKC TECHNOLOGY, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090107520-A1 | AMIDOXIME COMPOUNDS AS CHELATING AGENTS IN SEMICONDUCTOR PROCESSES | EKC TECHNOLOGY, INC. | 2009-04-30 | — | — | US | disclosed |
| EP-1824479-B1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-11-05 | — | — | EP | disclosed |
| EP-1824479-B1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| EP-1827427-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| EP-1824479-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2007-08-29 | — | — | EP | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| WO-2006061376-A1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL D0PAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006061378-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060122190-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | disclosed |
| WO-2005023783-A1 | PROCESS FOR THE MANUFACTURE OF GEFITINIB | ASTRAZENECA AB (SE) | 2005-03-17 | — | — | WO | disclosed |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | SANKYO AGRO COMPANY, LIMITED (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| EP-1426365-A1 | 3-PHENOXY-4-PYRIDAZINOL DERIVATIVE AND HERBICIDE COMPOSITION CONTAINING THE SAME | Sankyo Agro Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-0923568-B9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2003-08-13 | — | — | EP | disclosed |
| EP-1086096-B1 | BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS | ALTANA PHARMA AG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-1278750-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-01-29 | — | — | EP | disclosed |
| EP-0923568-B1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| EP-0912568-B1 | IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2002-11-20 | — | — | EP | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001083485-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
| US-6303789-B1 | TREATING AIRWAY DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-10-16 | — | — | US | disclosed |
| CN-1313284-A | N-(3-benzofuryl) urea derivative | BAYER AG (DE) | 2001-09-19 | — | — | CN | disclosed |
| US-6211203-B1 | RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
| EP-1086096-A1 | BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6020340-A | Imidazopyridines | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-02-01 | — | — | US | disclosed |
| WO-1999064414-A1 | BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-16 | — | — | WO | disclosed |
| EP-0923568-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| EP-0912568-A1 | NOVEL IMIDAZOPYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998007715-A9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998007715-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997043288-A1 | NOVEL IMIDAZOPYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-11-20 | — | — | WO | disclosed |
| CN-1134419-A | N- (3-benzofuranyl) urea derivatives | BAYER AG (DE) | 1996-10-30 | — | — | CN | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (37 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | AR 1394/4885P4HB 1226/4885CYP19A1 124/4885 |
| US-20100137586-A1 | Process for the Preparation of Gefitinib | EGFR, BRAF, KRAS | AR 1656/4885P4HB 2984/4885CYP19A1 140/4885 |
| US-20060122247-A1 | Aryloxyethylamine and phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2A, HTR2C, HTR1A | AR 138/4885P4HB 4663/4885CYP19A1 900/4885 |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | AR 2912/4885P4HB 930/4885CYP19A1 978/4885 |
| US-20160237076-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, DCTD | AR 4080/4885P4HB 3968/4885CYP19A1 4854/4885 |
| US-11446307-B2 | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof | DCK, DTYMK, PRKDC | AR 4784/4885P4HB 3808/4885CYP19A1 4362/4885 |
| US-20220133735-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | DCK, DTYMK, PRKDC | AR 4784/4885P4HB 3808/4885CYP19A1 4362/4885 |
| US-20060122190-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | AR 667/4885P4HB 4012/4885CYP19A1 1414/4885 |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | AR 805/4885P4HB 2320/4885CYP19A1 1659/4885 |
| US-10251886-B1 | 4-anilinoquinazoline derivative and albumin conjugates thereof | KRAS, NRAS, ALB | AR 1560/4885P4HB 1614/4885CYP19A1 1502/4885 |
| US-20190016714-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | DCK, DTYMK, DCTD | AR 4589/4885P4HB 3266/4885CYP19A1 4824/4885 |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | XRCC6, XRN2, HRH2 | AR 631/4885P4HB 3434/4885CYP19A1 927/4885 |
| US-20160200688-A1 | Process of Preparing a Quinazoline Derivative | ABL1, EGFR, KRAS | AR 1761/4885P4HB 3385/4885CYP19A1 522/4885 |
| US-20210069219-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | AR 1461/4885P4HB 1560/4885CYP19A1 129/4885 |
| US-20090286982-A1 | NOVEL SALT-554 | KRAS, NISCH, WASHC4 | AR 4308/4885P4HB 2273/4885CYP19A1 3147/4885 |
| US-20250049808-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | DCK, DTYMK, PRKDC | AR 4784/4885P4HB 3808/4885CYP19A1 4362/4885 |
| US-20100041555-A1 | 3-Phenoxy-4-pyridazinol derivatives and herbicidal composition containing the same | CBR3, DDT, CBR1 | AR 1506/4885P4HB 534/4885CYP19A1 551/4885 |
| US-20220135555-A1 | CRYSTALLINE FORMS OF A DEOXYCYTIDINE KINASE INHIBITOR AND USES THEREOF | DCK, DTYMK, PRKDC | AR 4784/4885P4HB 3808/4885CYP19A1 4362/4885 |
| US-20090137191-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | PADI2, PADI4, PADI3 | AR 4765/4885P4HB 290/4885CYP19A1 2902/4885 |
| US-20140194485-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | IDO1, CYP11B2, IDO2 | AR 313/4885P4HB 3192/4885CYP19A1 201/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | AR 3058/4885P4HB 942/4885CYP19A1 1233/4885 |
| US-20200108083-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | AR 1461/4885P4HB 1560/4885CYP19A1 129/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | AR 1461/4885P4HB 1560/4885CYP19A1 129/4885 |
| US-20130336883-A1 | DEOXYCYTIDINE KINASE BINDING COMPOUNDS | DCK, DTYMK, DCTD | AR 4423/4885P4HB 4394/4885CYP19A1 4758/4885 |
| US-20060003999-A1 | Process for the preparation of 4-(3'-chloro-4'-fluoroanilino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline | CYP3A7, CYP3A5, CYP4B1 | AR 4882/4885P4HB 667/4885CYP19A1 665/4885 |
| US-20170204090-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, DCTD | AR 4080/4885P4HB 3968/4885CYP19A1 4854/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | AR 3117/4885P4HB 1483/4885CYP19A1 1179/4885 |
| US-20150258063-A1 | ISOTOPOLOGUES OF ISOINDOLE DERIVATIVES | IDO1, CYP11B2, IDO2 | AR 313/4885P4HB 3192/4885CYP19A1 201/4885 |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | CDK7, CCNC, CDC73 | AR 4316/4885P4HB 2583/4885CYP19A1 869/4885 |
| US-20100217027-A1 | PROCESS FOR PRODUCTION PHENOL DERIVATIVES SUBSTITUTED WITH IODINE AT ORTHO POSITION | TPO, TH, HPD | AR 3013/4885P4HB 70/4885CYP19A1 775/4885 |
| US-10570124-B2 | Deoxycytidine kinase binding compounds | DCK, DTYMK, DCTD | AR 4589/4885P4HB 3266/4885CYP19A1 4824/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | AR 3249/4885P4HB 1177/4885CYP19A1 714/4885 |
| US-10946031-B2 | PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol | PDE4A, PDE4B, PDE12 | AR 843/4885P4HB 1220/4885CYP19A1 1711/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | AR 805/4885P4HB 2320/4885CYP19A1 1659/4885 |
| US-20120108814-A1 | PROCESS 738 | CYP2C8, CYP4F8, UGT1A8 | AR 4724/4885P4HB 1378/4885CYP19A1 1807/4885 |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | AR 1254/4885P4HB 227/4885CYP19A1 161/4885 |
| US-20050037925-A1 | 3-phenoxy-4-pyridazinol derivatives and herbicide composition containing the same | CBR3, DDT, CHRM2 | AR 1570/4885P4HB 467/4885CYP19A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.